{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-014239","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.869285+00:00","generated_at":"2026-06-04T11:23:05.277529+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Femasys: 24% pregnancy rate with FemaSeed in severe male factor infertility trial, more than triple IUI rate","bullets":["Pivotal trial: 24% of women became pregnant after FemaSeed in severe male factor (TMSC 1M-20M), vs 6.7% per cycle for IUI in literature.","Majority of successful pregnancies required only one FemaSeed procedure.","No new safety concerns; adverse events mild and consistent with known IUI events.","FDA clearance obtained September 2023; commercial launch planned first half of 2024.","Capital infusion at end of 2023 provides funding into second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-014239","json":"https://secwatch.observer/filing/0001140361-24-014239.json","markdown":"https://secwatch.observer/filing/0001140361-24-014239.md","text":"https://secwatch.observer/filing/0001140361-24-014239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/0001140361-24-014239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124014239/ef20024684_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:23:05.277529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}